TLON receives positive ODAC vote. AVII files shelf. CYTR reverse split vote date set + MNOV news

Mar 22, 2012 No Comments by

Talon Therapeutics, Inc., (OTCBB:TLON), announced the Oncologic Drugs Advisory Committee voted 7 yes, 4 no, and 2 abstain for a  favorable benefit/risk assessment for use of Marqibo for the treatment of adult Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or that has progressed following two or more lines of anti-leukemia therapy. The PDUFA date for Marqibo is May 13, 2012.

AVI BioPharma, Inc. (NASDAQ: AVII) filed a mixed shelf allowing it, from time to time in one or more offerings, offer and sell up to $100m in the aggregate of common stock, preferred stock, debt securities, warrants to purchase common stock, preferred stock or debt securities.

CytRx Corporation (NASDAQ:CYTR) said in a SEC filing that it intends to seek shareholder approval on May 14, 2012, to effect a reverse stock split in the range of between 1-for-3 and 1-for-12. The company earlier mentioned that it received notification on February 15, 2012 that because it had not regained compliance with the $1.00 minimum bid price requirement for continued listing, it would be subject to delisting from The NASDAQ Capital Market on or before February 22, 2012, unless it requested a hearing before a NASDAQ Hearings Panel. The company subsequently scheduled a meeting before the Panel.

According to NASDAQhearings are typically scheduled 30 to 45 days from the company’s request. The Panel generally issues a written decision approximately 35 days after the hearing, but the company could receive a written decision sooner. 

Using the timeline supplied by NASDAQ above, a decision is likely to be rendered by NASDAQ between late-April and mid-May 2012.

MediciNova, Inc. (Nasdaq:MNOV) announced it has completed enrollment in its Phase 2 trial of MN-221 for treatment of acute exacerbations of asthma. Preliminary results are due 2Q 2012.

Daily News

About the author

Currently residing in New Zealand and employed in the education industry, Mr. A. Burden holds a M.Com in International Business from the University of Sydney and used these skills together with his passion for investing to establish BioPharmCatalyst in June 2010 as a tool for investing decisions in the US pharmaceutical market. He spends much of his free time mountain biking, playing squash and hiking.
No Responses to “TLON receives positive ODAC vote. AVII files shelf. CYTR reverse split vote date set + MNOV news”

Leave a Reply